pipeline

TAB Bio is a next-generation biotechnology company focused on accelerating the development of innovative therapies through a capital-efficient and de-risked model. By leveraging an in-licensing, development, and out-licensing strategy, TAB Bio acquires promising but underdeveloped biopharmaceutical assets, advances them through key clinical milestones, and partners with leading pharmaceutical companies for commercialization.

At TAB Bio, we target high-impact therapeutic areas, including oncology, immunology, and rare diseases, where unmet medical needs persist. Through strategic in-licensing from academic institutions, small biotechs, and pharmaceutical companies, we identify assets with strong scientific rationale and clinical potential. Our agile development framework allows us to optimize clinical pathways, mitigate regulatory risks, and enhance asset value efficiently.

TAB Bio redefines how novel therapeutics are developed and commercialized in the biotech industry by combining scientific expertise, operational excellence, and a business model designed for capital efficiency.